NextGen Healthcare, Inc. provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools. Its products also comprise NextGen Enterprise PM, a practice management (PM) solution; and NextGen Office, a cloud-based electronic health record and PM solution. In addition, the company offers automation and workflow solutions, including NextGen Mobile Health Solutions, NextGen Electronic Healthcare Transactions, NextGen Pre-Service Clearance, and NextGen Patient Payment solutions. Further, it provides analytics, population health, and patient engagement solutions, such as NextGen Population Health Informed Analytics, NextGen Population Health Patient Care Coordination, NextGen Population Health Performance Management, and NextGen Patient Portal solutions. Additionally, the company offers NextGen Connected Health and NextGen Share interoperability solutions. It also provides professional services, including training, project management, functional and detailed specification preparation, configuration, testing, installation, support, and client services. It serves physician hospital and management service organizations, independent physician associations, accountable care organizations, ambulatory care centers, and community health centers through a sales force and reseller channel. NextGen Healthcare, Inc. has a strategic partnership with OTTO Health LLC. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was founded in 1974 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Computer integrated systems design
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone949-255-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$529.17 million
Profitability
Miscellaneous
Employees2,660
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable
Nextgen Healthcare (NASDAQ:NXGN) Frequently Asked Questions
What is Nextgen Healthcare's stock symbol?
Nextgen Healthcare trades on the NASDAQ under the ticker symbol "NXGN."
How were Nextgen Healthcare's earnings last quarter?
Nextgen Healthcare Inc (NASDAQ:NXGN) issued its quarterly earnings results on Tuesday, October, 30th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.19 by $0.05. The firm had revenue of $130.30 million for the quarter, compared to the consensus estimate of $134.55 million. Nextgen Healthcare had a net margin of 4.37% and a return on equity of 10.05%. The company's revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.22 EPS. View Nextgen Healthcare's Earnings History.
When is Nextgen Healthcare's next earnings date?
What price target have analysts set for NXGN?
8 equities research analysts have issued 12-month price objectives for Nextgen Healthcare's stock. Their predictions range from $1.00 to $23.00. On average, they expect Nextgen Healthcare's share price to reach $15.57 in the next year. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for Nextgen Healthcare.
What is the consensus analysts' recommendation for Nextgen Healthcare?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nextgen Healthcare in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nextgen Healthcare.
What are Wall Street analysts saying about Nextgen Healthcare stock?
Here are some recent quotes from research analysts about Nextgen Healthcare stock:
- 1. According to Zacks Investment Research, "NextGen exited the fiscal first quarter on a dull note, with earnings and revenues missing the consensus mark. However, the company witnessed significant deal-size growth in the quarter under review. Solid bookings growth in the quarter deserves a mention as well. Impressive rates of client addition have worked well for NextGen. Expansion in operating margin is an added positive. On the flip side, the company’s Recurring and Software, Hardware and Other non-recurring revenues were soft in the quarter under review. The company’s top line also fell on a year-over-year basis. Significant contraction in gross margin raises concern. Slashed guidance for fiscal 2020 raises concern as well. Additionally, NextGen faces stiff rivalry in the MedTech space. The stock has underperformed the industry over the past year." (7/30/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on NXGN shares and maintain our price target of $23. We recently met with NXGN management team. We remain confident that some of the issues that came up with its F2Q19 results (reported in late October) were temporary in nature. As a reminder, F2Q19 bookings were about $36 million, representing growth of 39% y/y, which is impressive. However, as deal size increases, implementation timelines expand and short-term revenue is not hitting expectations. The company also experienced higher-than-expected customer attrition. After considering the elevated attrition during the quarter and the company’s expectation that it will remain elevated for some time, we reduced our F20 revenue growth assumption to 5.7% from 7.0%." (12/6/2018)
Has Nextgen Healthcare been receiving favorable news coverage?
News coverage about NXGN stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nextgen Healthcare earned a news impact score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Nextgen Healthcare.
Are investors shorting Nextgen Healthcare?
Nextgen Healthcare saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 2,190,000 shares, a decrease of 5.2% from the August 15th total of 2,310,000 shares. Based on an average trading volume of 326,600 shares, the short-interest ratio is currently 6.7 days. Currently, 4.5% of the shares of the stock are sold short. View Nextgen Healthcare's Current Options Chain.
Who are some of Nextgen Healthcare's key competitors?
Some companies that are related to Nextgen Healthcare include Parsons (PSN), Verint Systems (VRNT), Scientific Games (SGMS), Allscripts Healthcare Solutions (MDRX), NetScout Systems (NTCT), Sykes Enterprises (SYKE), Ebix (EBIX), Agilysys (AGYS), Simulations Plus (SLP), Ribbon Communications (RBBN), Onespan (OSPN), Tufin Software Technologies (TUFN), Digimarc (DMRC), Unisys (UIS) and Travelzoo (TZOO).
What other stocks do shareholders of Nextgen Healthcare own?
Who are Nextgen Healthcare's key executives?
Nextgen Healthcare's management team includes the folowing people:
- Mr. John R. Frantz, Pres, CEO & Director (Age 52)
- Mr. James Robert Arnold Jr., Exec. VP, CFO & Principal Accounting Officer (Age 63)
- Mr. David A. Metcalfe, Exec. VP & Chief Technology Officer (Age 56)
- Mr. Jeffrey D. Linton, Exec. VP, Gen. Counsel & Sec. (Age 56)
- Mr. Scott E. Bostick, Non-Exec. Officer (Age 54)
Who are Nextgen Healthcare's major shareholders?
Nextgen Healthcare's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Smith Graham & Co. Investment Advisors LP (0.77%), State of Alaska Department of Revenue (0.06%), Virginia Retirement Systems ET AL (0.05%), Bowling Portfolio Management LLC (0.04%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Nextgen Healthcare stock include George H Bristol and Sheldon Razin. View Institutional Ownership Trends for Nextgen Healthcare.
Which institutional investors are selling Nextgen Healthcare stock?
NXGN stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC and Meeder Asset Management Inc.. Company insiders that have sold Nextgen Healthcare company stock in the last year include George H Bristol and Sheldon Razin. View Insider Buying and Selling for Nextgen Healthcare.
Which institutional investors are buying Nextgen Healthcare stock?
How do I buy shares of Nextgen Healthcare?
Shares of NXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nextgen Healthcare's stock price today?
One share of NXGN stock can currently be purchased for approximately $15.86.
How big of a company is Nextgen Healthcare?
Nextgen Healthcare has a market capitalization of $1.04 billion and generates $529.17 million in revenue each year. The company earns $24.49 million in net income (profit) each year or $0.61 on an earnings per share basis. Nextgen Healthcare employs 2,660 workers across the globe.View Additional Information About Nextgen Healthcare.
What is Nextgen Healthcare's official website?
How can I contact Nextgen Healthcare?
Nextgen Healthcare's mailing address is 18111 Von Karman Avenue Suite 800, Irvine CA, 92612. The company can be reached via phone at 949-255-2600 or via email at [email protected]
MarketBeat Community Rating for Nextgen Healthcare (NASDAQ NXGN)
MarketBeat's community ratings are surveys of what our community members think about Nextgen Healthcare and other stocks. Vote "Outperform" if you believe NXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
